Invivyd (NASDAQ:IVVD) Insider Jill Andersen Sells 30,706 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 30,706 shares of Invivyd stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total value of $25,793.04. Following the completion of the sale, the insider directly owned 283,774 shares of the company’s stock, valued at $238,370.16. The trade was a 9.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jill Andersen also recently made the following trade(s):

• On Monday, August 17th, Jill Andersen sold 37,256 shares of Invivyd stock. The stock was sold at an average price of $0.72, for a total transaction of $26,824.32.

Invivyd Stock Up 17.2%

Shares of IVVD opened at $0.87 on Wednesday. Invivyd, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $3.07. The firm’s 50 day moving average price is $0.77 and its 200 day moving average price is $1.23. The company has a market cap of $255.75 million, a P/E ratio of -2.63 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last released its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The company had revenue of $14.29 million during the quarter, compared to analysts’ expectations of $14.40 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. Research analysts forecast that Invivyd, Inc. will post -0.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. BTIG Research restated a “buy” rating on shares of Invivyd in a research note on Tuesday, July 7th. HC Wainwright reiterated a “buy” rating on shares of Invivyd in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. Finally, Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.00.

Key Headlines Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. United Capital Financial Advisors LLC purchased a new position in Invivyd during the second quarter worth $84,000. Bank of America Corp DE acquired a new position in shares of Invivyd during the 2nd quarter valued at about $311,000. Jupiter Topco LLC purchased a new position in Invivyd during the second quarter worth approximately $30,048,000. ADAR1 Capital Management LLC purchased a new position in shares of Invivyd in the 2nd quarter worth $3,322,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Invivyd in the 2nd quarter worth about $52,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.